Strs Ohio Invests $102,000 in Amicus Therapeutics, Inc. (FOLD) Stock
Strs Ohio bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,800 shares of the biopharmaceutical company’s stock, valued at approximately $102,000.
A number of other hedge funds also recently bought and sold shares of the business. BNP Paribas Arbitrage SA increased its holdings in shares of Amicus Therapeutics by 3,672.2% during the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after purchasing an additional 66,209 shares during the period. Goldman Sachs Group Inc. increased its stake in Amicus Therapeutics by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock worth $5,541,000 after purchasing an additional 41,711 shares in the last quarter. Alliancebernstein L.P. increased its stake in Amicus Therapeutics by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock worth $2,073,000 after purchasing an additional 28,800 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in Amicus Therapeutics in the 2nd quarter worth about $1,057,000. Finally, Bank of Nova Scotia acquired a new stake in Amicus Therapeutics during the 2nd quarter worth about $1,944,000.
In related news, SVP Daphne Quimi sold 7,000 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John F. Crowley sold 71,735 shares of Amicus Therapeutics stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $14.75, for a total value of $1,058,091.25. Following the transaction, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,615,664.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 628,224 shares of company stock worth $9,024,003. Corporate insiders own 3.40% of the company’s stock.
Amicus Therapeutics, Inc. (FOLD) opened at $12.89 on Friday. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.35 and a current ratio of 6.32.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The company had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. During the same period last year, the company posted ($0.33) earnings per share. The business’s revenue for the quarter was up 419.0% on a year-over-year basis. analysts anticipate that Amicus Therapeutics, Inc. will post -1.51 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/strs-ohio-invests-102000-in-amicus-therapeutics-inc-fold-stock/1697688.html.
FOLD has been the topic of a number of recent analyst reports. BidaskClub raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Robert W. Baird reissued an “outperform” rating and issued a $16.00 price objective on shares of Amicus Therapeutics in a research note on Monday, September 25th. Chardan Capital reaffirmed a “buy” rating and issued a $16.50 price target (down from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Finally, Bank of America Corporation lifted their price target on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $17.81.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.